In-vitro susceptibilities of species of the Bacteroides fragilis group to newer β -lactam agents | Zendy

Carmen Betriú | Zendy; Ana M. Sánchez | Zendy; Maria F. Gomez | Zendy; M. Luisa Palau | Zendy; Juan J. Picazo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In-vitro susceptibilities of species of the Bacteroides fragilis group to newer β -lactam agents

Author(s) -

Carmen Betriú,

Ana M. Sánchez,

Maria F. Gomez,

M. Luisa Palau,

Juan J. Picazo

Publication year - 1999

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/43.1.133

Subject(s) - bacteroides fragilis , microbiology and biotechnology , lactam , in vitro , bacteroides , moxalactam , cephalosporin , beta lactam , biology , chemistry , antibiotics , bacteria , stereochemistry , biochemistry , genetics

The in-vitro activities of imipenem and four beta-lactam-beta-lactamase inhibitor combinations were tested against 816 strains of the Bacteroides fragilis group, and compared with other anti-anaerobic agents. None of the strains was resistant to metronidazole, and only one was resistant to chloramphenicol. Mezlocillin and piperacillin were moderately active, while clindamycin was the least active. Rates of resistance varied between various species. The new beta-lactam agents tested showed excellent activity; piperacillin-tazobactam and imipenem were the most active. The emergence of strains that are resistant to these agents, observed in this study, suggests there is a need to perform periodic antimicrobial susceptibility tests.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research